Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 1;9:117. doi: 10.3389/fonc.2019.00117

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 van den Heuvel, van Ewijk, Zeelen, de Bitter, Huynen, Mulders, Oosterwijk and Leenders.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Combination therapy of MET inhibitors Compound A and cabozantinib with an EGFR inhibitor (gefitinib) or G6PD inhibitor (6AN) in (A) SKRC7 and (B) SKRC17 cell lines. Drug effects were tested using SRB assays. The FA-value represents the fraction of cell viability affected by therapy. Points on the graph axes represent the dose of the monotherapy (drug A or B, as indicated in the figure head of each isobologram) necessary to generate the given FA-value. The line connecting the x- and y-axis represents an additive effect (CI = 1) of the combination at the given FA-value. Points below or above the line represent synergism (CI < 1.0) or antagonism (CI > 1.0), respectively (N = 2).